Maverick Therapeutics Acquisition, Valuation, Funding & Investors

Shoreline Biosciences is a biotechnology company developing allogeneic, off-the-shelf cellular immunotherapies for cancer, using induced pluripotent stem cells (iPSCs) to derive natural killer cell and macrophage therapies for solid tumors and blood cancers. Founded in 2020 by Kleanthis Xanthopoulos and based in San Diego, the company builds smart manufacturing capabilities to support its pipeline and holds strategic partnerships with Kite, a Gilead company, and BeiGene for cell therapy development.

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Strand Therapeutics is a Cambridge-headquartered biotechnology firm founded in 2017 that engineers programmable mRNA medicines using synthetic biology principles. The platform deploys logic circuits within cells to detect tumor-specific signals and produce cancer-fighting proteins on demand, such as cytokines for immunotherapy. Their lead candidates target solid tumors including glioblastoma and head-and-neck cancers through intravenous administration. Strand Therapeutics collaborates with academic institutions like MIT and has progressed multiple programs into preclinical testing for oncology applications.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Ollin Biosciences is an Austin, Texas-based clinical-stage biopharmaceutical company that acquires and develops bispecific antibody therapies for vision-threatening eye diseases rather than pursuing in-house drug discovery. Its lead candidate, OLN324, is a VEGF/Ang2 bispecific antibody licensed from China's Innovent Biologics that is advancing toward Phase 3 trials for diabetic macular edema and wet age-related macular degeneration. A second program, OLN102, licensed from VelaVigo, is a TSHR/IGF-1R bispecific antibody in development for thyroid eye disease and Graves' disease.

SmartCella is a Milan-based biotechnology company advancing cell therapy delivery for cardiac regeneration. Its SmartCella device enables precise intracoronary injection of stem cells, drugs, and RNA therapeutics during procedures. Tested in preclinical models for heart failure and myocardial infarction, it partners with clinics in Italy and the EU. Founded in 2016, SmartCella focuses on interventional cardiology applications.

Yantai Lannacheng Biotechnology is a Yantai-based biotechnology company that develops class I integrated platforms for diagnosis and therapy using novel nuclear radiopharmaceuticals targeting tumors. The firm advances research in targeted radionuclide therapies and diagnostic agents for oncology applications. Its platform supports development of precision medicines for cancer treatment in China.

Ring Therapeutics is a biotechnology company developing Anellovector gene therapies derived from human commensal viruses for redosable and targeted treatments. Backed by Flagship Pioneering and based in Cambridge, Massachusetts, it advances platforms beyond traditional gene replacement for diseases like liver disorders and muscle wasting. Founded in 2022, Ring Therapeutics pioneers viral vectors for immunology and oncology applications.

Expedition Therapeutics is a San Diego-headquartered clinical-stage biotech developing oral therapies for inflammatory respiratory diseases. Its lead candidate, EXPD-101, inhibits dipeptidyl peptidase 1 to reduce neutrophilic inflammation in chronic obstructive pulmonary disease and bronchiectasis. The company completed Phase 1 trials in 2023 and plans Phase 2 studies in 2024 across Europe and North America. Expedition in-licenses assets while building internal pipelines, supported by a team from GSK and AstraZeneca. It operates R&D facilities in La Jolla, California.

Umoja Biopharma engineers in vivo CAR T-cell therapies that reprogram patients' T cells to attack solid tumors and hematological malignancies resistant to existing treatments. Seattle-headquartered, the company advances its AlloVector platform for localized immune cell activation without ex vivo manipulation. Partnerships with Biogen and Takeda support clinical progression in oncology pipelines targeting glioblastoma and other cancers.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Chabiotech Co Ltd is engaged in the manufacturing of biological products.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

TaiMed Biologics Inc is a biotechnology company committed to have the expertise and capability in developing, manufacturing and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 (TMB-365 and TMB-380 combination), and Antibody-Drug Conjugates, ADCs.

Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.